- Open Access
Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo: implication of RRM2 in angiogenesis
© Zhang et al; licensee BioMed Central Ltd. 2009
- Received: 21 January 2009
- Accepted: 28 February 2009
- Published: 28 February 2009
In addition to its essential role in ribonucleotide reduction, ribonucleotide reductase (RNR) small subunit, RRM2, has been known to play a critical role in determining tumor malignancy. Overexpression of RRM2 significantly enhances the invasive and metastatic potential of tumor. Angiogenesis is critical to tumor malignancy; it plays an essential role in tumor growth and metastasis. It is important to investigate whether the angiogenic potential of tumor is affected by RRM2.
We examined the expression of antiangiogenic thrombospondin-1 (TSP-1) and proangiogenic vascular endothelial growth factor (VEGF) in two RRM2-overexpressing KB cells: KB-M2-D and KB-HURs. We found that TSP-1 was significantly decreased in both KB-M2-D and KB-HURs cells compared to the parental KB and mock transfected KB-V. Simultaneously, RRM2-overexpressing KB cells showed increased production of VEGF mRNA and protein. In contrast, attenuating RRM2 expression via siRNA resulted in a significant increased TSP-1 expression in both KB and LNCaP cells; while the expression of VEGF by the two cells was significantly decreased under both normoxia and hypoxia. In comparison with KB-V, overexpression of RRM2 had no significant effect on proliferation in vitro, but it dramatically accelerated in vivo subcutaneous growth of KB-M2-D. KB-M2-D possessed more angiogenic potential than KB-V, as shown in vitro by its increased chemotaxis for endothelial cells and in vivo by the generation of more vascularized tumor xenografts.
These findings suggest a positive role of RRM2 in tumor angiogenesis and growth through regulation of the expression of TSP-1 and VEGF.
- Vascular Endothelial Growth Factor
- Human Umbilical Vein Endothelial Cell
- Vascular Endothelial Growth Factor Expression
- LNCaP Cell
- Vascular Endothelial Growth Factor mRNA
Ribonucleotide reductase (RNR) plays an essential role in catalyzing conversion of ribonucleoside diphosphates to the corresponding 2'-deoxyribonucleoside diphosphates, a rate-limiting step in the production of 2'-deoxyribonucleoside 5'-diphosphates (dNTP) required for DNA synthesis and repair . Human ribonucleotide reductase consists of two subunits: RRM1 and RRM2, both proteins are required for enzymatic activity. The cellular RRM1 protein level remains relatively stable throughout the entire cell cycle, whereas RRM2 is only expressed during the late G1/early S phase, and degraded in late S phase. The activity of RNR, and therefore DNA synthesis and cell proliferation, is controlled during the cell cycle by the synthesis and degradation of RRM2 subunit . RRM2 itself is a dimmer of two 44 kDa moieties, each containing non-heme iron that stabilizes a unique tyrosyl-free radical required for enzyme activity . Recently cloned p53R2, a new RNR family member, encodes a protein with striking similarity to RRM2, which is induced by UV light, γ-irradiation or adriamycin in a wild type p53-dependent manner . p53R2 directly participates in p53-directed repair of damaged DNA through generating a RNR holoenzyme with RRM1 to synthesize the dNTPs for DNA repair .
Many studies have demonstrated that increased RNR enzymatic activity is tightly associated with tumor progression and malignancy. Alteration in the activity of RNR has been identified in a variety of tumor cells obtained from mouse and human tissues [6–8]. Apart from the well-known role in ribonucleotide reduction, several studies have indicated that RRM1 and RRM2 may play opposite roles in controlling malignant progression of tumor cells. Studies had identified that overexpression of both mice R1 and human RRM1 significantly inhibited in vivo tumor growth and decreased metastatic potential of tumor through activating PTEN pathway [9–11]. Conversely, overexpression of mouse R2 markedly enhanced cellular transforming potential of various oncogenes; and increased malignant potential of transformed cells [11–13]. We and others had reported that overexpression of human RRM2 could enhance the invasive and metastatic potential of various human cancer cells [14–16]. Our recent study had also shown that the RRM2 protein level in human colon cancer was positively correlated to the metastasis of colon cancer, and elevated RRM2 may serve as a potential biomarker for metastasis of colon cancer [8, 14].
Angiogenesis, the formation of new blood vessel from pre-existing vessel, plays a critical role in many physiological and pathological conditions including embryonic development, wound healing, tumor growth and metastasis [17, 18]. Angiogenesis is tightly controlled by a balance of pro-angiogenic and anti-angiogenic factors . Among many angiogenesis factors, vascular endothelial growth factor (VEGF) is one of the most critical and specific factors that stimulate both physiological and pathological angiogenesis; the expression of VEGF are induced by growth factors and hypoxia . Whereas, among many antiangiogenic factors, thrombospondin-1 (TSP-1) is a very potent angiogenesis inhibitor, and down-regulation of TSP-1 has been suggested to alter tumor growth by modulating angiogenesis in a variety of tumor types . Oncogenes activation and loss of tumor suppressor genes activity can directly regulate the expression of proangiogenic and antiangiogenic factors in an opposite way thus determining the overall angiogenic activity of tumors . In tumor cells, VEGF is also stimulated by mutated ras, v-src, c-fos and c-jun etc . The expression of TSP-1 is upregulated by the tumor suppressor gene, p53, and down-regulated by oncogenes such as myc and ras [20–22].
Tumor angiogenesis is a hallmark of malignancy; it plays an essential role in tumor growth and metastasis . However, the implication of the RRM2 in tumor angiogenesis is not closely studied. Therefore, in the present study, we examined the impact of the RRM2 on tumor angiogenesis through its regulating the expression of proangiogenic factor VEGF, and antiangiogenic factor TSP-1. For the first time, we found overexpression of RRM2 alone reduces TSP-1 expression; induced VEGF expression in tumor cells, resulted in a tumor xenograft with more angiogenic potential and accelerated growth in vivo. Our results indicate a positive role of RRM2 in tumor angiogenesis and progression.
Human oropharyngeal carcinoma KB cells (American Type Culture Collection, Manassas, VA), were cultured in a 5% CO2 atmosphere at 37°C on plastic tissue culture plates in DMEM supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. RRM2-overexpressing KB-M2-D and the mock-transfected KB-V were cultured in the same medium of KB cells with 300 μg/ml G-418 . KB-HURs, a hydroxyurea-resistant clone with an elevated RRM2 protein induced by hydroxyurea, was incubated and maintained in the presence of 1 mM hydroxyurea  as another RRM2-overexpressing cells clone in this study. The human prostate adenocarcinoma LNCaP was cultured in RPMI1640 medium containing 10% heat-inactivated fetal bovine serum (FBS; Gibco BRL, Grant Island, NY, USA) and 1 mM sodium pyruvate. For cell culture under hypoxia, cells were grown in a chamber containing 1% O2, 5% CO2 and 94% N2 at 37°C.
Quantitative reverse transcriptional PCR: q-RT-PCR
Total RNA was extracted from cells by using of Qiagen RNeasy Min Kit. Residual genomic DNA was removed by incubating the RNA with DNase (Qiagen, Valencia, CA). cDNA was synthesized from 1.0 μg of total RNA using the Superscript III first-strand cDNA synthesis kit (Invitrogen, Carlsbad, CA) in a final volume of 20 μl with 0.25 μg random hexamer and 200 Units of Superscript RNase H-reverse transcriptase. The reaction mixture was firstly incubated at 25°C for 5 min, and then followed by incubation at 50°C for 50 min. Quantitative real time PCR was carried out in the ABI Prism 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA). The reaction mixture of 20 μl consisted of 1× ABI SYBR Green PCR Master Mix, 0.25 μl cDNA and 0.2 μM of each primer. The PCR protocol was: 95°C for 10 min, followed by 40 cycles of 95°C for 15 s, 60°C 1 min. The following primers were used: RRM2, 5'-GCGATTTAGCCAAGAAGTTCAGAT-3' (forward) and 5'-CCCAGTCTGCCTTCTTCTTGA-3' (reverse); TSP-1, 5'-ACGAGGAATGGACTGTTGATAGC-3' (forward) and5'-ATCAGGAACTGTGGCATTGGAG-3' (reverse). VEGF, 5'-CCAGCACATAGGAGAGATGAGCTT-3' (forward) 5'-TCTTTCTTTGGTCTGCATTCACAT-3' (reverse). Beta-Actin, 5'-ATCTGGCACCACACCTTCTACAA-3' (forward) 5'-GTACATGGCTGGGGTGTTGAAG-3' (reverse).
Relative gene-expression quantification method was used to calculate the fold change of mRNA expression according to the comparative Ct method using β-actin as an endogenous control. Final results were determined as follows: 2-(ΔCt sample-ΔCt control), where ΔCt values of the control and sample were determined by subtracting the Ct value of the target gene from the value of the housekeeping gene: β-actin. Data was represented as ratio or folds change to control sample.
RRM2 siRNA Knockdown assay
The human RRM2 gene specific siRNA (sc-36338) and scramble siRNA were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). 5 × 105/well KB cells were cultured in six-well plates with 2-mL antibiotic-free growth medium at 37°C in a CO2 incubator for 24 hours. siRNA duplex-Lipofectamine was prepared by 6.0 μL of 10 μmol/L RRM2 siRNA or scramble siRNA and 3.0 μl Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA) in 500 μl serum-free OptiMEM medium (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions, and directly added into the media. 24 or 48 h after transfection, cells was collected . The knockdown of RRM2 was measured by quantitative reverse transcription-PCR (q-RT-PCR) and Western blot.
Preparation of conditioned medium and ELISA assay
Cells were seeded in 35 mm dishes in 2 ml of growth medium to reach approximately 80% confluence. Cells were washed with PBS 3 times and then were either cultured for 24 h under normoxic or hypoxic condition in 2 ml of serum free medium at 37°C. Cell supernatants were collected, clarified by centrifugation at 2000 rpm for 5 min, and stored at -80°C. Concomitantly, the cell pellets were used in parallel for RT-PCR and total protein concentration. Condition medium for samples of RRM2 knockdown was collected as following. Firstly, cells were cultured in complete medium for 24 h post-transfection under normoxia. Then, cells were further cultured in serum free medium for 24 h under either normoxia or hypoxia (1% O2), and the medium was collected. The amount of VEGF in condition medium was measured with a QuantikineTM immunoassay kit (VEGF-ELISA R&D system, Minneapolis, MN, USA) following the manufacturer's instructions. VEGF was expressed as ng of VEGF protein/ml of medium and per mg of total protein.
Western blot analysis
The mouse monoclonal antibodies against Beta-Actin, RRM2, were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Mouse monoclonal antibody against human TSP-1 was purchased from Thermo Scientific (Fremont, CA). Western blot was conducted as previously described . Briefly, about 20-μg total protein was separated by 10% SDS-PAGE, transferred to a Nitrocellulose membrane (Bio-Rad Laboratories, CA) and incubated in blocking buffer (1% I-Block reagent and 0.1% Tween 20) with the primary antibody (1:1000 dilution) overnight at 4°C. After 3–5 washes, the membrane was incubated with fluorescent-labeled secondary antibodies (1:8,000 dilutions) for 60 minutes. After sequential washes, membranes were scanned on an Odyssey Infrared Imaging System (LI-COR Biosciences). Signals were densitometrically assessed and normalized to the β-actin signals.
Human umbilical vein endothelial cell migration assay
Modified Boyden chambers (Millicell PCF, 8 μm pore size; Millipore) were placed in a 24-well plate and coated with 10 μg/ml collagen I (Roche Diagnostics) overnight. After washing with PBS, 0.6 ml of concentrated condition media was placed in the bottom chamber. HUVEC cells were cultured in complete EBM-2 medium (Cambrex Bioscience, MD, USA), and passage 5–6 of HUVEC was used for the experiment. After starvation for 16 h, 2 × 105 human umbilical vein endothelial cells (HUVEC) were resuspended in 0.3 ml DMEM/0.1% BSA, plated in the top of the transwell chambers, and incubated for 24 h at 37°C with 5% CO2. Cells were removed from the upper membrane surface with a cotton tip applicator, washed with PBS, and cells on the lower membrane surface were fixed and stained (Hema 3 Stain System; Fisher Diagnostics). HUVEC migration was quantified by manually counting the number of cells on the inserts under high-power at ×100 magnification. The migration of HUVEC added to the upper compartment of the chamber, was expressed as the number of cells migrated in 10 high-power fields. Values were expressed as the mean ± SD of two independent tests; each test included three individual wells .
In vitro proliferation and in vivo growth
0.5 × 104 of KB-V and KB-M2-D cells were replated into wells of 16-well devices compatible with a W200 real-time cell electronic sensing (RT-CES) analyzer and 16× station (Acea Biosciences, San Diego, CA). Cell growth was monitored periodically (typically, every 0.5 or 1 h) for indicated durations via calculation of a "cell index" (normalized impedance) for each well. Unless otherwise indicated, cells from each well of the original six-well plates were replated into four replicate wells for cell index measurement.
The animal protocol for tumorigenicity assay in vivo was approved by the Institutional Animal Care and Use Committee of City of Hope Medical Center with RACC protocol number 0750. 6 to 8t-week-old Nod-Scid mice (City of Hope) were subcutaneously inoculated in the right flank with either 5 × 106 KB-V or KB-M2-D cells resuspended in 100 μL serum-free RPMI. Tumor xenografts appeared approximately 3–6 days following cell injection. Tumor xenograft diameters were measured with digital calipers twice a week, and the tumor volume in mm3 was calculated by the formula: Volume = (width)2 × length/2; and results were presented as mean tumor volume ± SD of two independent experiments. Mouse was sacrificed on 30th day after inoculation. Tumor xenografts were dissected and the final volume and wet weight were determined. Subsequently, they were cut through the median, one part was fixed in formalin and embedded in paraffin, the other part was embedded in Tissue-Tek and snap frozen in liquid nitrogen.
Immonostainig IHC Microvessel analysis
For immunohistochemical analysis of CD31 (a specific marker of endothelial cells), formalin fixed and paraffin embedded tumor sections were permeabilized with 36 μg/ml proteinase K and stained with a rat anti-mouse CD31 antibody (clone MEC13.3, BD Biosciences), final dilution 1:250. Tyramide signal amplication kits (PerkinElmer Life and Analytical sciences, Inc.) were used with Cyanine 3 red fluorescence. Microvessel density was qualitatively assessed by examining the entire vital cellular zone of the tumors according to the described procedure . Microvessel count was carried out on three fields (×100) chosen within the whole vascularized areas. Any endothelial cell or cluster of endothelial cells positive for CD31 was counted.
Data were collected using an MS-Excel spreadsheet. Data were analyzed using the JMP Statistical Discovery Software version 6.0 (SAS Institute, Cary, NC). Group comparisons for continuous data were done with student's t-test for independent means or two-way ANOVA. Statistical significance was set at P < 0.05.
Overexpression of RRM2 decreased TSP-1 expression in KB Cells
Among many anti-angiogenic factors, TSP-1 is a very critical angiogenic inhibitor; it can directly inhibit endothelial cell migration and proliferation [21, 24]. We examined the protein levels of TSP-1 in total protein extracts (abbreviated as TSP1-T in Figure 1a) and equally concentrated condition mediums (abbreviated as TSP1-CM in Figure 1a) from KB, KB-V, KB-M2-D, and KB-HURs. Western-blot analysis displayed that both RRM2-overexpressing KB-M2-D, and KB-HURs cells showed a dramatic decrease in TSP-1 protein compared to control KB and KB-V cells (Figure 1a, b). To investigate whether the decreased TSP-1 protein was due to reduced synthesis at mRNA level, we also measured by q-RT-PCR the TSP-1 mRNA levels in cells. We found, in both RRM2-overexpressing cells, the TSP-1 mRNA levels were significantly decreased (Figure 1d, P < 0.01).
Overexpression of RRM2 increased VEGF expression in KB Cells
Knockdown of RRM2 increased TSP-1 and decreased VEGF expression in both KB and LNCaP Cells
RRM2-overexpressing KB-M2-D cells showed accelerative tumor growth in vivo
Overexpression of RRM2 promoted angiogenic potential of tumors in vitro and in vivo
Tumor angiogenesis is controlled by a balance of pro-angiogenic and anti-angiogenic factors [18–20]. We questioned whether the increased production of angiogenic factors VEGF and the parallel reduction of the inhibitor TSP-1 by RRM2 would affect the angiogenic potential of tumors. In vitro, we measured the ability of condition medium collected from KB-V and KB-M2-D cell lines to affect endothelial cell motility, a crucial event of the angiogenic process, known to be modulated by the VEGF and TSP-1 etc [18–20]. Using the Boyden chamber assay, we identified the HUVEC attracted by condition medium of KB-M2-D was 78.3 ± 10.7 (mean ± SD), and that attracted by condition medium of KB-V was 25.6 ± 6.4; statistic analysis indicated that the condition medium of the KB-M2-D were significantly more active in stimulating the migration of HUVEC cells in comparison with that of control KB-V cells (p < 0.01).
RRM2 is well-known as small subunit of RNR, a rate-limiting enzyme for dNDP synthesis required for DNA replication [1–3]. High RNR enzymatic activity is associated with tumor progression and resistance to various cellular stressors such as chemotherapeutic agents and ionizing radiation [6–8]. Increased RRM2 and RNR enzymatic activity were reported to present in highly metastatic tumor cells and tissues [9–11]. Therefore, RRM2 is also an important therapeutic target for DNA replication-dependent diseases such as cancer. Recently, many studies have demonstrated that RRM2 plays additional roles in determining the malignant potential of tumor cells. For example, elevated expression of RRM2 has been found to increase the drug-resistant properties of cancer cells and significantly enhance the invasive potential of many human cancer cells [3, 9, 10, 15], whereas knockdown of RRM2 expression results in the reversal of drug-resistance and suppressed tumor growth, and decreased metastasis potential [14, 16, 25]. Studies have identified that overexpression of both RRM1 and RRM2 leads increased RR activities and expended dNTP pools [[9, 13, 15], and ]. Interestingly, two recent studies have the studies found that overexpression of RRM1 suppresses invasion and metastasis formation of tumors through induction of PTEN pathway [9–11]. These data suggest two subunits of RNR play opposing roles in tumor progression and malignancy; beside they cooperate in dNTP production.
Tumor angiogenesis is necessary for the growth and metastasis of many tumors. Potential of angiogenic switch is a critical character of tumor malignancy [17–19]. Tumor angiogenesis and metastatic formation are intrinsically connected [20, 27]. Accumulating evidences support RRM2 possesses oncogene-like properties; it plays a potential role in tumor malignancy and metastasis. In this study, we therefore focused on the effect of RRM2 on tumor angiogenesis. We investigated the effect of overexpression of RRM2 on the production of angiogenesis regulatory factors in human cancer cells. Our study demonstrated that overexpression of RRM2 decreased the production of TSP-1 and increased that of VEGF in KB cells. Because hypoxia is a critical factor regulating VEGF expression through stabilizing its transcriptional factor HIF-1 protein and it is also an essential factor for tumor development . We also examined the effect of RRM2 on VEGF expression under hypoxia condition. The data demonstrated that under hypoxia condition overexpression of RRM2 further increased VEGF protein in KB cells. To further confirm the regulation, we measured TSP-1 and VEGF expression in KB and LNCaP cells after RRM2 knockdown by its specific siRNA. Contrast to overexpression of RRM2, we found knockdown of RRM2 expression caused an increased TSP-1 and decreased VEGF expression in both KB and LNCaP cells. Considering the potential therapeutic application of RNA interference for RRM2 such as siRNA, antisense oligo-nucleotide [16, 25], our above finding is potentially important, and it also indicates that the therapy based on RNA interference for RRM2 may potentially inhibit tumor angiogenesis beside its known inhibitory effects [16, 25]. The changes in the expression of angiogenic factors: TSP-1 and VEGF induced by RRM2 in tumor cells did result in increased angiogenic activity in vitro, as shown by the increased chemotactic activity for endothelial cells. Moreover, tumors generated in vivo by RRM2-overexpressing cells showed a higher vascular density compared to controls. We supposed that higher vascular density might partially contribute to growth advantage of RRM2-overexpressing cancer cells. Consistent with what we expected, the increased vascularization caused by overexpression of RRM2 did confer a growth advantage to RRM2-overexpressing cancer cells.
VEGF is significantly associated with poor outcome in human various malignancies [29, 30]. The increased production of VEGF is significant for various cancers development. Exposure of tumor cells to hypoxia is a common finding in solid tumors. Hypoxia induces a myriad of adaptive changes within tumor cells, which result in increased anaerobic glycolysis, new blood vessel formation and genetic instability . Consistently, a previous study by Graff et al  also found that elevated RNR caused by overexpression of RRM2 could overrule long-lasting arrest of DNA-synthesis after severe hypoxia insult, and cancer cells with elevated RRM2 were more resistant to hypoxia. TSP-1 is an important inhibitor of angiogenesis, and its suppression is crucial for the angiogenic switch in many tumor models [[32, 33], and ]. Additionally, TSP-1 is an inhibitor of invasion; it inhibits the activity of matrix metalloproteinase-9 (MMP9), which causes release of vascular endothelial growth factor sequestered in the extracellular matrix, thereby increasing invasion potential . Coincidentally, a recent study of Duxbury et al  also found that overexpression of RRM2 increased pancreatic adenocarcinoma cellular invasiveness and MMP-9 expression.
The earlier study by Wright et al [12, 13] reported that mouse RRM2 synergize with a variety of oncogenes including h-ras, h-rac, v-src, a-raf, c-myc, etc in cellular transformation and tumorigenic potential to normal fibroblast cells through a variety of signal pathways. For example, cooperation with Ras, overexpression of mouse RNR small subunit R2 significantly increases membrane-associated Raf-1 protein and MAPK-2 activity, finally further activates MAPK pathway . Oncogenes not only promote aberrant cellular mitogenesis, but also have an important impact on tumor formation and growth through an indirect mechanism, namely, by driving tumor angiogenesis [20–22]. Oncogenes such as v-myc, c-jun, v-src h-ras etc down-regulate the TSP-1 expression [20–22]. Additionally, some of them – for example, h-ras and c-myc – also significantly up-regulate VEGF expression . Contrast to oncogenes, tumor suppressor genes such as p53, Rb and PTEN etc stimulate TSP-1 expression [20–22]. Interestingly, our previous study found that in cancer cells, even without any stress RRM2 and p53R2 are bound to wild-type p53 protein. In response to UV irradiation, RRM2 and p53R2 dissociate themselves from p53 and form RNR with RRM1 . It is interesting to further examine whether elevated RRM2 has any impact on p53 function through the protein-protein interaction. Coincidently, we found that knockdown of RRM2 leads a significantly elevated p53 protein in both KB and LNCaP (unpublished data); we are focusing on the correlations among these proteins. Since p53 acts as a negative controller of angiogenesis, and the loss of functional p53 results in high VEGF and low TSP-1 production, with consequent increase in angiogenic activity . The mechanisms through which RRM2 regulate TSP-1 and VEGF expression requires further investigation.
Overexpression of RRM2 in KB cell suppressed TSP-1 expression, and increased VEGF expression. Conversely, attenuating RRM2 expression via siRNA resulted in a significant increased TSP-1 expression and decreased VEGF production in both KB and LNCaP cells. Our study demonstrated that overexpression of RRM2 substantially promoted the in vivo growth of tumor cells, and positively affected the overall angiogenic activity of tumor cells. Knockdown of RRM2 by RNA interference such as siRNA may potentially inhibit cancer angiogenesis.
We thank Dr. David Ann (City of Hope National Medical Center, Duarte, CA 91010, USA) for his critical discussion on the study; and Dr. Frank Hong (City of Hope National Medical Center, Duarte, CA 91010, USA) for his critical review of the manuscript.
- Nordlund P, Reichard P: Ribonucleotide reductases. Annu Rev Biochem. 2006, 75: 681-706. 10.1146/annurev.biochem.75.103004.142443View ArticlePubMedGoogle Scholar
- Engstrom Y, Eriksson S, Jildevik I, Skog S, Thelander L, Tribukait B: Cell cycle-dependent expression of mammalian ribonucleotide reductase. Differential regulation of the two subunits. J Biol Chem. 1985, 260: 9114-9161.PubMedGoogle Scholar
- Zhou B, Yen Y: Characterization of the human ribonucleotide reductase M2 subunit gene; genomic structure and promoter analyses. Cytogenet Cell Genet. 2001, 95: 52-59. 10.1159/000057017View ArticlePubMedGoogle Scholar
- Tanaka H, Arakawa H, Yamaguchi T, Shiraishi K, Fukuda S, Matsui K, Takei Y, Nakamura Y: A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature. 2000, 404: 42-49. 10.1038/35003506View ArticlePubMedGoogle Scholar
- Guittet O, Håkansson P, Voevodskaya N, Gräslund A, Arakawa H, Nakamura Y, Thelander L: Mammalian p53R2 protein forms an active ribonucleotide reductase in vitro with the R1 protein, which is expressed both in resting cells in response to DNA damage and in proliferating cells. J Biol Chem. 2001, 276: 40647-40651. 10.1074/jbc.M106088200View ArticlePubMedGoogle Scholar
- Jensen RA, Page DL, Holt JT: Identification of genes expressed in premalignant breast disease by microscopy-directed cloning. Proc Natl Acad Sci USA. 1994, 91: 9257-9261. 10.1073/pnas.91.20.9257PubMed CentralView ArticlePubMedGoogle Scholar
- Schallreuter KU, Elgren TE, Nelson LS, MacFarlan S, Yan-Sze I, Hogenkamp HP: Ribonucleotide diphosphate reductase from human metastatic melanoma. Melanoma Res. 1992, 2: 393-400. 10.1097/00008390-199212000-00014View ArticlePubMedGoogle Scholar
- Liu X, Zhou B, Xue L, Yen F, Chu P, Un F, Yen Y: Ribonucleotide reductase subunits M2 and p53R2 are potential biomarkers for metastasis of colon cancer. Clin Colorectal Cancer. 2007, 6: 374-381. 10.3816/CCC.2007.n.007View ArticlePubMedGoogle Scholar
- Fan H, Huang A, Villegas C, Wright JA: The R1 component of mammalian ribonucleotide reductase has malignancy-suppressing activity as demonstrated by gene transfer experiments. Proc Natl Acad Sci USA. 1997, 94: 13181-13186. 10.1073/pnas.94.24.13181PubMed CentralView ArticlePubMedGoogle Scholar
- Gautam A, Li ZR, Bepler G: RRM1-induced metastasis suppression through PTEN-regulated pathways. Oncogene. 2003, 22: 2135-2142. 10.1038/sj.onc.1206232View ArticlePubMedGoogle Scholar
- Cao MY, Lee Y, Feng NP, Xiong K, Jin H, Wang M, Vassilakos A, Viau S, Wright JA, Young AH: Adenovirus-mediated ribonucleotide reductase R1 gene therapy of human colon adenocarcinoma. Clin Cancer Res. 2003, 9: 4553-61.PubMedGoogle Scholar
- Fan H, Villegas C, Huang A, Wright JA: The mammalian ribonucleotide reductase R2 component cooperates with a variety of oncogenes in mechanisms of cellular transformation. Cancer Res. 1998, 58: 1650-1653.PubMedGoogle Scholar
- Fan H, Villegas C, Wright JA: Ribonucleotide reductase R2 component is a novel malignancy determinant that cooperates with activated oncogenes to determine transformation and malignant potential. Proc Natl Acad Sci USA. 1996, 93: 14036-14040. 10.1073/pnas.93.24.14036PubMed CentralView ArticlePubMedGoogle Scholar
- Liu X, Zhou B, Xue L, Shih J, Tye K, Lin W, Qi C, Chu P, Un F, Wen W, Yen Y: Metastasis-suppressing potential of ribonucleotide reductase small subunit p53R2 in human cancer cells. Clin Cancer Res. 2006, 12: 6337-6344. 10.1158/1078-0432.CCR-06-0799View ArticlePubMedGoogle Scholar
- Zhou B, Tsai P, Ker R, Tsai J, Ho R, Yu J, Shih J, Yen Y: Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential. Clin Exp Metastasis. 1998, 16: 43-49. 10.1023/A:1006559901771View ArticlePubMedGoogle Scholar
- Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE: RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene. 2004, 23: 1539-1548. 10.1038/sj.onc.1207272View ArticlePubMedGoogle Scholar
- Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995, 1: 27-31. 10.1038/nm0195-27View ArticlePubMedGoogle Scholar
- Carmeliet P: Angiogenesis in health and disease. Nat Med. 2003, 9: 653-660. 10.1038/nm0603-653View ArticlePubMedGoogle Scholar
- Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996, 86: 353-364. 10.1016/S0092-8674(00)80108-7View ArticlePubMedGoogle Scholar
- Semenza GL: Angiogenesis in ischemic and neoplastic disorders. Annu Rev Med. 2003, 54: 17-28. 10.1146/annurev.med.54.101601.152418View ArticlePubMedGoogle Scholar
- Ren B, Yee KO, Lawler J, Khosravi-Far R: Regulation of tumor angiogenesis by Thrombospondin-1. Biochim Biophys Acta. 2006, 1765 (2): 178-188.PubMedGoogle Scholar
- Rak J, Yu JL, Kerbel RS, Coomber BL: What do oncogenic mutations have to do with angiogenesis/vascular dependence of tumors?. Cancer Res. 2002, 62: 1931-1934.PubMedGoogle Scholar
- Hanahan D, Weinberg RA: The Hallmarks of Cancer. Cell. 2000, 100: 57-70. 10.1016/S0092-8674(00)81683-9View ArticlePubMedGoogle Scholar
- Short SM, Derrien A, Narsimhan RP, Lawler J, Ingber DE, Zetter BR: Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats is mediated by β1 integrins. J Cell Biol. 2005, 168: 643-653. 10.1083/jcb.200407060PubMed CentralView ArticlePubMedGoogle Scholar
- Heidel JD, Liu JY, Yen Y, Zhou B, Heale BS, Rossi JJ, Bartlett DW, Davis ME: Potent siRNA Inhibitors of Ribonucleotide Reductase Subunit RRM2 Reduce Cell Proliferation In vitro and In vivo. Clin Cancer Res. 2007, 13: 2207-2215. 10.1158/1078-0432.CCR-06-2218View ArticlePubMedGoogle Scholar
- Zhou B, Ker R, Ho R, Yu J, Zhao YR, Shih J, Yen Y: Determination of deoxyribonucleoside triphosphate pool sizes in ribonucleotide reductase cDNA transfected human KB cells. Biochem Pharmacol. 1998, 55: 1657-1665. 10.1016/S0006-2952(98)00042-2View ArticlePubMedGoogle Scholar
- Bergers G, Benjamin LE: Angiogenesis: Tumorigenesis and the angiogenic switch. Nature Reviews Cancer. 2003, 3: 401-410. 10.1038/nrc1093View ArticlePubMedGoogle Scholar
- Harris AL: Hypoxia – a key regulatory factor in tumor growth. Nat Rev Cancer. 2002, 2: 38-47. 10.1038/nrc704View ArticlePubMedGoogle Scholar
- Bando H, Weich HA, Brokelmann M, Horiguchi S, Funata N, Ogawa T, Toi M: Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer. Br J Cancer. 2005, 92: 553-561.PubMed CentralPubMedGoogle Scholar
- Koukourakis MI, Giatromanolaki A, Thorpe PE, Brekken RA, Sivridis E, Kakolyris S, Georgoμlias V, Gatter KC, Harris AL: Vascular Endothelial Growth Factor/KDR Activated Microvessel Density versus CD31 Standard Microvessel Density in Non-Small Cell Lung Cancer. Cancer Res. 2000, 60: 3088-3095.PubMedGoogle Scholar
- Graff P, Seim J, Amellem Ø, Arakawa H, Nakamura Y, Andersson KK, Stokke T, Pettersen EO: Counteraction of pRb-dependent protection after extreme hypoxia by elevated ribonucleotide reductase. Cell Prolif. 2004, 37: 367-383. 10.1111/j.1365-2184.2004.00319.xView ArticlePubMedGoogle Scholar
- Gutierrez LS, Suckow M, Lawler J, Ploplis VA, Castellino FJ: Thrombospondin 1-a regulator of adenoma growth and carcinoma progression in the APCMin/+ mouse model. Carcinogenesis. 2003, 24: 199-207. 10.1093/carcin/24.2.199View ArticlePubMedGoogle Scholar
- Yang QW, Liu S, Tian Y, Salwen HR, Chlenski A, Weinstein J, Cohn SL: Methylation-associated silencing of the thrombospondin-1 gene in human neuroblastoma. Cancer Res. 2003, 63: 6299-6310.PubMedGoogle Scholar
- Watnick RS, Cheng YN, Rangarajan A, Ince TA, Weinberg RA: Ras modμlates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell. 2003, 3: 219-231. 10.1016/S1535-6108(03)00030-8View ArticlePubMedGoogle Scholar
- Rodriguez-Manzaneque JC, Lane TF, Ortega MA, Hynes RO, Lawler J, Iruela-Arispe ML: Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc Natl Acad Sci USA. 2001, 98: 12485-12490. 10.1073/pnas.171460498PubMed CentralView ArticlePubMedGoogle Scholar
- Duxbury MS, Whang EE: RRM2 induces NF-kappaB-dependent MMP-9 activation and enhances cellular invasiveness. Biochem Biophys Res Commun. 2007, 354: 190-196. 10.1016/j.bbrc.2006.12.177View ArticlePubMedGoogle Scholar
- Xue L, Zhou B, Liu X, Qiu W, Jin Z, Yen Y: Wild-Type p53 regulates human ribonucleotide reductase by protein-protein Interaction with p53R2 as well as RRM2 Subunits. Cancer Res. 2003, 63: 980-986.PubMedGoogle Scholar
- Volpert OV, Dameron KM, Bouck N: Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity. Oncogene. 1997, 27 (14): 1495-502. 10.1038/sj.onc.1200977. 10.1038/sj.onc.1200977View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.